No Detail Found!

E ectiveness and Safety of Memantine Add-on Treatment for Refractory Obsessive-Compulsive Disorder: A Meta-Analysis

Author(s)
Wenxuan Zhang The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China ;Department of Psychiatry, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China
Yuhan Zhang The Second School of Clinical Medicine, Zhejiang Chinese Medical University,Hangzhou,China
Enyan Yu Department of Psychiatry, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital),Hangzhou,China
Abstract
Obsessive compulsive disorder (OCD) is a highly disabling mental illness characterised by repetitive thoughts and behaviours that disrupt daily life and impair social functioning. The purpose of this meta-analysis was to assess the e cacy and safety of memantine augmentation in treating refractory OCD. This study searched several databases from inception to January 2024 and performed a random-e ects metaanalysis with subgroup analyses to evaluate the e ects of the dose and duration of the intervention. Seven randomised controlled trials involving 315 participants were included, although signi cant heterogeneity existed between the studies. Memantine augmentation was signi cantly superior to a placebo in treating OCD (SMD = -1.17, 95% CI = -2.14 to -0.20, p = 0.02). Subgroup analysis revealed that memantine signi cantly reduced compulsive behaviours (SMD = -0.99, 95% CI = -1.45 to -0.52, p <0.001). After eight weeks of treatment, the memantine group showed a signi cant improvement in the total Yale Brown Obsessive Compulsive Scale (Y-BOCS) score compared with the placebo group (SMD = -1.06, 95% CI = -1.77 to -0.36, p = 0.003). The memantine group showed a signi cant improvement in the total Y-BOCS score at a dose of 20 mg/day (SMD = -1.06, 95% CI = -1.77 to -0.36, p = 0.003). Memantine signi cantly increased the risk of mild rash (relative risk = 7.00, 95% CI = 1.31 37.47, p = 0.02). Memantine is safe and e ective for OCD augmentation therapy at 20 mg/day and a continued intervention of at least eight weeks.
Publication Details
Page(s) 494-502
Published Journal: Journal of the College of Physicians and Surgeons Pakistan, Volume: 35, Issue: 04, Year: 2025

Request the full text from PASTIC

Keywords
Safety, Memantine, E cacy, Obsessive compulsive disorder, augmentation
References
Bottoms L,Pons MP,Fineberg NA,Pellegrini L,Fox A,Wellsted D .2022 .of exercise on obsessivecompulsive disorder symptoms: A systematic review and meta-analysis. Int J Psychiatry Clin, 2151474(3) : 232-42.
de la Cruz LF,Isomura K,Lichtenstein P,Ruck C,Cols DM .2022 .Morbidity and mortality in obsessive-compulsive disorder: A narrative review. Neurosci Biobehav Rev, 104602 : 104602.
Cervin M. .2022 .Obsessive-compulsive disorder: Diagnosis, clinical features, nosology, and epidemiology. Psychiatric Clin North Am, 10(1) : 1-6.
Xie L,Hu P,Guo Z,Chen M,Wang X,Du X .2024 .Immediate and long-term e cacy of transcranial direct stimulation (tCDS) in obsessive-compulsive disorder, posttraumatic stress disorder and anxiety disorders: A systematic review and meta-analysis. Transl Psychiatry, 10(1) : 343.
Biria M,Banca P,Healy MP,Keser E,Sawiak SJ,Rodgers CT .2023 .Cortical glutamate and GABA are related to compulsive behaviour in individuals with obsessive compulsive disorder and healthy controls. Nat Commun, 10(1) : 3324.
Chohan MO,Kopelman JM,Yueh H,Fazlali Z,Greene N,Harris AZ .2022 .Developmental impact of glutamate transporter overexpression on dopaminergic neuron activity and stereotypic behavior. Mol Psychiatry, 10(3) : 1515-26.
Vlcek P,Polak J,Brunovsky M,Horacek J .2018 .Role of glutamatergic system in obsessive-compulsive disorder with possible therapeutic implications. Pharmacopsychiatry, 10(6) : 229-42.
Pittenger C .2015 .Glutamate modulators in the treatment of obsessive-compulsive disorder. Psychiatric Ann, 10(6) : 00485713-15.
Escobar AP,Wendland JR,Chavez AE,Moya PR .2019 .The neuronal glutamate transporter EAAT3 in obsessive-compulsive disorder. Front Pharmacol, 01362 : 1362.
Bufan B,Curuvija I,Blagojevic V,Milanovic JG,Prijic I,Radosavljevic T .2024 .NMDA receptor antagonist memantine ameliorates experimental autoimmune encephalomyelitis in aged rats. Biomedicines, 10(4) : 717.
Elnaiem W,Benmelouka AY,Elgendy AMN,Abdelgalil MS,Alsaman MZB,Mogheeth A .2022 .Evaluation of memantine's e cacy and safety in the treatment of children with autism spectrum disorder: A systematic review and meta-analysis. Hum Psychopharmacol, 10(5) : .
Shah NM,Ghazaryan N,Gonzaga NL,Paclibar CG,Biju AP,Liang C .2023 .Glutamate's e ects on the N-Methyl-D-aspartate (NMDA) receptor ion channel in alzheimer's disease brain: Challenges for PET radiotracer development for imaging the NMDA ion channel. Molecules, 10(1) : 20.
Bakhla AK,Verma V,Soren S,Sarkhel S,Chaudhury S. .2013 .An open-label trial of memantine in treatment-resistant obsessivecompulsive disorder. Ind Psychiatry J, 10(2) : 132930-6748.
.2023 .trichotillomania and skin-picking disorder. Am J Psychiatry, 20220737(5) : 348-56.
Kishi T,Matsuda Y,Iwata N. .2018 .Combination therapy of serotonin reuptake inhibitors and memantine for obsessivecompulsive disorder: A meta-analysis of double-blind, randomized, placebo-controlled trials. J Alzheimer's Dis, 10(1) : 43-8.
Modarresi A,Chaibakhsh S,Koulaeinejad N,Koupaei SR .2019 .A current systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder. Psychiatry Res, 112602 : 112602.
Hadi F,Kamalzadeh S,Hoobehfekr Shalbafan M. L .2021 .Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: A systematic review and meta-analysis. BMC Pharmacol Toxicol, 10(1) : 69.
Moher D,Shamseer L,Clarke M,Ghersi D,Liberati A,Petticrew M .2015 .4(1):1. Sys Rev, 10 : .
Hauschildt M,Dar R,Schroder J,Moritz S. Congruence .2019 .and discrepancy between self-rated and clinician-rated symptom severity on the yale-brown obsessive-compulsive scale (YBOCS) before and after a low-intensity intervention. Psychiatry Res, 01 : 595-602.
Yan J,Gu Y,Wang M,Cui Y,Li Y. .2022 .The obsessive-compulsive symptoms in tic disorders and the psychometric properties of children's yale-brown obsessive-compulsive scale: An evidence-based survey in a Chinese sample. Front Pediatr, 794188 : 794188.
Feingold .2009 .A. E ect sizes for growth-modeling analysis for controlled clinical trials in the same metric as for classical analysis. Psychol Methods, 10(1) : 43-53.
Jun L .2019 .E cacy and tolerability of memantine in refractory obsessive-compulsive disorder. J Int Psychiatry, 02(02) : 266-9.
Sahraian A,Jahromi LR,Ghanizadeh A,Mowla A .2017 .Memantine as an adjuvant treatment for obsessive compulsive symptoms in manic phase of bipolar disorder: A randomized, double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol, 10(2) : 246-9.
Modarresi A,Sayyah M,Razooghi S,Eslami K,Javadi M,Kouti L M .2018 .Memantine augmentation improves symptoms in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: A randomized controlled trial. Pharmacopsychiatry, 10(6) : 263-9.
Haghighi M,Jahangard L,Beigi HM,Bajoghli H,Hafezian H,Rahimi A .2013 .In a double-blind, randomized and placebocontrolled trial, adjuvant memantine improved symptoms in inpatients su ering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology (Berl), 10(4) : 633-40.
Grant JE,Chesivoir E,Valle S,Ehsan D,Chamberlain SR . .Double-blind placebo-controlled study of memantine in. , : .
Ghaleiha A,Entezari N,Modabbernia A,Najand B,Askari N,Tabrizi M .2012 .Memantine add-on in moderate to severe obsessive-compulsive disorder: Randomized double-blind placebo-controlled study. J Psychiatr Res, 09(2) : 175-80.
Farnia V,Gharehbaghi H,Alikhani M,Almasi A,Golshani S,Tatari F .2018 .and tolerability of adjunctive gabapentin and memantine in obsessive compulsive disorder: Double-blind, randomized, placebo-controlled trial. J Psychiatr Res, 07 : 137-43.
Askari S,Mokhtari S,Shariat SV,Shariati B,Yarahmadi M,Shalbafan M. .2022 .Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial. BMC Psychiatry, 10(1) : 34.
Targa L,Mottarlini G,Thielens F,Rizzi S,Villers B,A B .2024 .Memantine-induced functional rewiring of the glutamate synapse in the striatum of dopamine transporter knockout rats. Br J Pharmacol, 10(6) : 1377-93.
Marinova Z,Chuang DM,Fineberg N DM .2017 .Glutamate-modulating drugs as a potential therapeutic strategy in obsessivecompulsive disorder. Curr Neuropharmacol, 10(7) : 977-95.
Norman LJ,Carlisi CO,Christakou A,Cubillo A,Murphy CM,Chantiluke K .2017 .Shared and disorder-speci c task-positive and default mode network dysfunctions during sustained attention in paediatric attention-de cit/ hyperactivity disorder and obsessive/compulsive disorder. NeuroImage Clin, 04 : 181-93.
Beucke JC,Sepulcre J,Talukdar T,Linnman C,Zschenderlein K,Endrass T .2013 .Abnormally high degree connectivity of the orbitofrontal cortex in obsessive-compulsive disorder. JAMA Psychiatry, 173(6) : 619-29.
Starkiewicz AC,Noworyta K,Solich J,Korlatowicz A,Gorecka AF,Rygula R .2024 .Identi cation of genes regulated by sensitivity to negative feedback and prolonged alcohol consumption in rats. Pharmacol Rep, 10(1) : 207-15.
Netto VM,Flores CA,Pallanti S. .2020 .Pharmacological treatment for comorbid bipolar disorder and obsessive-compulsive disorder in adults. J Psychiatr Pract, 10(5) : 383-93.
0

Citations

0

Downloads

79

Views